Logo image of NRIX

NURIX THERAPEUTICS INC (NRIX) Stock Fundamental Analysis

NASDAQ:NRIX - Nasdaq - US67080M1036 - Common Stock - Currency: USD

11.52  -0.01 (-0.09%)

After market: 11.5219 +0 (+0.02%)

Fundamental Rating

4

NRIX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. While NRIX has a great health rating, there are worries on its profitability. NRIX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NRIX has reported negative net income.
In the past year NRIX has reported a negative cash flow from operations.
In the past 5 years NRIX always reported negative net income.
In the past 5 years NRIX always reported negative operating cash flow.
NRIX Yearly Net Income VS EBIT VS OCF VS FCFNRIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

NRIX has a better Return On Assets (-35.05%) than 61.51% of its industry peers.
The Return On Equity of NRIX (-46.32%) is better than 67.09% of its industry peers.
Industry RankSector Rank
ROA -35.05%
ROE -46.32%
ROIC N/A
ROA(3y)-37.56%
ROA(5y)-29.63%
ROE(3y)-55.97%
ROE(5y)-43.41%
ROIC(3y)N/A
ROIC(5y)N/A
NRIX Yearly ROA, ROE, ROICNRIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 200

1.3 Margins

NRIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRIX Yearly Profit, Operating, Gross MarginsNRIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

7

2. Health

2.1 Basic Checks

NRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NRIX has more shares outstanding
The number of shares outstanding for NRIX has been increased compared to 5 years ago.
There is no outstanding debt for NRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NRIX Yearly Shares OutstandingNRIX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NRIX Yearly Total Debt VS Total AssetsNRIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

NRIX has an Altman-Z score of 1.44. This is a bad value and indicates that NRIX is not financially healthy and even has some risk of bankruptcy.
NRIX has a better Altman-Z score (1.44) than 67.09% of its industry peers.
There is no outstanding debt for NRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.44
ROIC/WACCN/A
WACC9.75%
NRIX Yearly LT Debt VS Equity VS FCFNRIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

NRIX has a Current Ratio of 6.82. This indicates that NRIX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NRIX (6.82) is better than 66.01% of its industry peers.
NRIX has a Quick Ratio of 6.82. This indicates that NRIX is financially healthy and has no problem in meeting its short term obligations.
NRIX has a Quick ratio of 6.82. This is in the better half of the industry: NRIX outperforms 66.19% of its industry peers.
Industry RankSector Rank
Current Ratio 6.82
Quick Ratio 6.82
NRIX Yearly Current Assets VS Current LiabilitesNRIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.62% over the past year.
NRIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.85%.
The Revenue has been growing by 11.88% on average over the past years. This is quite good.
EPS 1Y (TTM)10.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.76%
Revenue 1Y (TTM)41.85%
Revenue growth 3Y22.4%
Revenue growth 5Y11.88%
Sales Q2Q%264.34%

3.2 Future

The Earnings Per Share is expected to grow by 9.57% on average over the next years. This is quite good.
NRIX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.60% yearly.
EPS Next Y-3.74%
EPS Next 2Y-9.88%
EPS Next 3Y-4.61%
EPS Next 5Y9.57%
Revenue Next Year32.08%
Revenue Next 2Y4.4%
Revenue Next 3Y13.73%
Revenue Next 5Y44.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NRIX Yearly Revenue VS EstimatesNRIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
NRIX Yearly EPS VS EstimatesNRIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRIX. In the last year negative earnings were reported.
Also next year NRIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRIX Price Earnings VS Forward Price EarningsNRIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRIX Per share dataNRIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

NRIX's earnings are expected to decrease with -4.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.88%
EPS Next 3Y-4.61%

More info and screens

0

5. Dividend

5.1 Amount

NRIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NURIX THERAPEUTICS INC

NASDAQ:NRIX (7/25/2025, 8:11:18 PM)

After market: 11.5219 +0 (+0.02%)

11.52

-0.01 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-09 2025-07-09/amc
Earnings (Next)10-09 2025-10-09/bmo
Inst Owners110.36%
Inst Owner Change-0.02%
Ins Owners1.41%
Ins Owner Change0.27%
Market Cap880.70M
Analysts84.17
Price Target30.53 (165.02%)
Short Float %18.9%
Short Ratio15.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.04%
Min EPS beat(2)13.97%
Max EPS beat(2)30.11%
EPS beat(4)3
Avg EPS beat(4)10.75%
Min EPS beat(4)-8.65%
Max EPS beat(4)30.11%
EPS beat(8)5
Avg EPS beat(8)2.48%
EPS beat(12)8
Avg EPS beat(12)4.82%
EPS beat(16)8
Avg EPS beat(16)1.87%
Revenue beat(2)2
Avg Revenue beat(2)98.12%
Min Revenue beat(2)42.3%
Max Revenue beat(2)153.94%
Revenue beat(4)4
Avg Revenue beat(4)50%
Min Revenue beat(4)1.28%
Max Revenue beat(4)153.94%
Revenue beat(8)5
Avg Revenue beat(8)15.4%
Revenue beat(12)7
Avg Revenue beat(12)6.55%
Revenue beat(16)10
Avg Revenue beat(16)3.73%
PT rev (1m)-1.19%
PT rev (3m)-1%
EPS NQ rev (1m)-3.95%
EPS NQ rev (3m)-2.27%
EPS NY rev (1m)2.73%
EPS NY rev (3m)3.06%
Revenue NQ rev (1m)10.91%
Revenue NQ rev (3m)12.37%
Revenue NY rev (1m)15.58%
Revenue NY rev (3m)16.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.96
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-2.61
EYN/A
EPS(NY)-3.49
Fwd EYN/A
FCF(TTM)-2.95
FCFYN/A
OCF(TTM)-2.81
OCFYN/A
SpS1.16
BVpS5.85
TBVpS5.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.05%
ROE -46.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.56%
ROA(5y)-29.63%
ROE(3y)-55.97%
ROE(5y)-43.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.04%
Cap/Sales 12.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.82
Quick Ratio 6.82
Altman-Z 1.44
F-Score4
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)115.59%
Cap/Depr(5y)151.67%
Cap/Sales(3y)19.87%
Cap/Sales(5y)20.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.76%
EPS Next Y-3.74%
EPS Next 2Y-9.88%
EPS Next 3Y-4.61%
EPS Next 5Y9.57%
Revenue 1Y (TTM)41.85%
Revenue growth 3Y22.4%
Revenue growth 5Y11.88%
Sales Q2Q%264.34%
Revenue Next Year32.08%
Revenue Next 2Y4.4%
Revenue Next 3Y13.73%
Revenue Next 5Y44.6%
EBIT growth 1Y-28.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.61%
EBIT Next 3Y-17.41%
EBIT Next 5YN/A
FCF growth 1Y-40.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.32%
OCF growth 3YN/A
OCF growth 5YN/A